Antigenic variation as an exploitable weakness of babesial parasites.
Babesia bovis and its bovine host interact in many ways, resulting in a range of disease and infection phenotypes. Host responses to the parasite elicit or select for a variety of responses on the part of the parasite, the full range of which is not yet known. One well-established phenomenon, thought to aid parasite survival by evasion of host adaptive immune responses, is the sequential expansion of antigenically variant populations during an infection, a phenomenon referred to as "antigenic variation". Antigenic variation in B. bovis, like that in the human malarial parasite, Plasmodium falciparum, is intimately linked to a second survival mechanism, cytoadhesion. In cytoadhesion, mature parasite-containing erythrocytes bind to the capillary and post-capillary venous endothelium through parasite-derived ligands. The reliance of these parasites on both functions, and on their linkage, may provide opportunities to develop anti-babesial and, perhaps, anti-malarial protection strategies. The development of inhibitors of DNA metabolism in B. bovis may be used to abrogate the process of antigenic variation, whereas small molecular mimics may provide the means to vaccinate against a wide range of variants or to prevent the surface export of variant antigen ligands. In this article, aspects of antigenic variation and cytoadhesion in bovine babesiosis are explored, with a discussion of opportunities for prophylactic or therapeutic intervention in these intertwined processes.
Allred
David R
DR
Department of Pathobiology, University of Florida, Gainesville, FL 32611-0880, USA. allredd@ufl.edu
Al-Khedery
Basima
B
D000818:Animals; D000940:Antigenic Variation / Q000235:genetics* / Q000276:immunology*; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology*; D000954:Antigens, Surface / Q000502:physiology; D016793:Babesia bovis / Q000235:genetics / Q000276:immunology*; D001404:Babesiosis / Q000276:immunology / Q000469:parasitology* / Q000517:prevention & control; D002448:Cell Adhesion / Q000502:physiology; D009154:Mutation / Q000235:genetics / Q000502:physiology; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology; D016052:Protozoan Vaccines / Q000276:immunology
D000953:Antigens, Protozoan; D000954:Antigens, Surface; D015800:Protozoan Proteins; D016052:Protozoan Vaccines